1. Academic Validation
  2. PD-L1 inhibition with MPDL3280A for solid tumors

PD-L1 inhibition with MPDL3280A for solid tumors

  • Semin Oncol. 2015 Jun;42(3):484-7. doi: 10.1053/j.seminoncol.2015.02.002.
Edward Cha 1 Jeffrey Wallin 2 Marcin Kowanetz 2
Affiliations

Affiliations

  • 1 Product Development Oncology, Genentech, Inc, South San Francisco, CA. Electronic address: cha.edward@gene.com.
  • 2 Oncology Biomarker Development, Genentech, Inc, South San Francisco, CA.
Abstract

Cancer Immunotherapy has become a popular Anticancer approach, with the goal of stimulating immune responses against tumor cells. Recent evidence has demonstrated that the use of monoclonal Antibodies targeting the programmed death ligand-1 (PD-L1)/programmed death-1 (PD-1) checkpoint pathway can result in well-tolerated clinical responses in a wide variety of tumor types. This review summarizes the safety, clinical activity and biomarker data for the anti-PD-L1 antibody, MPDL3280A, from a phase Ia multicenter, dose-escalation and -expansion trial. The data to date suggest that MPDL3280A is most effective in patients with pre-existing immunity suppressed by PD-L1 and reinvigorated upon antibody treatment.

Figures
Products